<< Global Health Partner utilizes existing share purchase warrants | BioClinica offers streamlined electronic transport solutions with the acquisition of CardioNow >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski

New market research report examines AMD and diabetic retinopathy pharmaceutical market

Published on September 1, 2009 at 7:07 AM · No Comments

Reportlinker.com announces that a new market research report is available in its catalogue.

Reportlinker Adds World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024

http://www.reportlinker.com/p0146155/Reportlinker-Adds-World-AMD-and-Diabetic-Retinopathy-Pharmaceutical-Market-2009-2024.html

With Increasing Retinal Disease Prevalence and Unmet Clinical Needs – Which Drug will be the Next Lucentis?

The global prevalences of AMD (age-related macular degeneration) and diabetic retinopathy are increasing due to rising numbers of older people worldwide. In addition, the world is facing a "diabetes epidemic", with rapidly-increasing numbers of people with diabetes and diabetic retinopathy. A clear market opportunity exists for pharmacological treatments for diabetic retinopathy, dry AMD and other retinal disorders. From 2009 to 2024, such treatments could repeat the commercial success that Lucentis achieved in the treatment of wet AMD. Our latest pharma report - World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 - examines prospects for the retinal disorder market over the next 15 years.

The rapid commercial success of Lucentis in treating wet AMD illustrates the high rewards for successful novel treatments in the retinal disorders market. There is a clear market opportunity for other drugs to treat diabetic retinopathy, a condition for which there are currently no approved pharmacological treatments. Our analysts believe there are further commercial opportunities for new treatments for geographic atrophy (advanced dry AMD) and for wet AMD. There is a need for clear advantages over existing wet AMD therapies, for improved clinical outcomes and ease of dosing. This report analyses prospects there.

Comprehensive analysis of the market area

World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 55 tables and figures and three full interviews with experts in the sector. The result is a comprehensive market- and industry-centred report, with detailed analyses and informed opinion to benefit your work.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading